Literature DB >> 19548446

[Treatment of lower extremity diabetic atherosclerotic obliterans with shuxuetong injection].

Kun Feng1, Jing-fan Tan, Ying Chen.   

Abstract

OBJECTIVE: To observe the effect and safety of Shuxuetong Injection (SXT) in treating patients with type 2 diabetes mellitus accompanying lower extremity atherosclerotic obliterans.
METHODS: The selected patients were assigned by randomized digital table to the treated group (180 cases treated with SXT) and the control group (80 cases treated with alprostadil). The clinical efficacy was assessed after 4 weeks of treatment, and the inner diameters and blood flow of the superficial femoral artery, the posterior tibial artery and the foot dorsal artery were measured and compared before and after treatment using Doppler's ultrasonography.
RESULTS: The total effective rate in the treated group was 94.4% (170/180), better than that in the control group, 85.0% (68/80, P < 0.01). Ultrasonic examination showed that the inner diameter and the blood flow of all the arteries measured in the treated groups increased after treatment (P < 0.01), with the increase superior to those in the control group (P < 0.05). No adverse reaction was found during the treatment.
CONCLUSION: SXT has the effect of activating blood circulation, dissolving stasis and dredging collaterals, it could reduce or eliminate the formation of thrombi, being effective and safe when applied in clinical practice for the treatment of lower extremity diabetic atherosclerotic obliterans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19548446

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

Review 1.  Prostanoids for critical limb ischaemia.

Authors:  Valeria Vietto; Juan Va Franco; Victoria Saenz; Denise Cytryn; Jose Chas; Agustín Ciapponi
Journal:  Cochrane Database Syst Rev       Date:  2018-01-10

2.  Shuxuetong injection simultaneously ameliorates dexamethasone-driven vascular calcification and osteoporosis.

Authors:  Zhe Xu; Xiaoguang Liu; Yanqing Li; Hongliang Gao; Tao He; Chunlei Zhang; Wei Hao; Xu Teng
Journal:  Exp Ther Med       Date:  2021-01-08       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.